Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Associated Therapies: -

Clinical Trials

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

Phase 4

Completed

Conditions: Clostridium Difficile

Interventions: Drug: Fidaxomicin
Drug: Vancomycin

First Posted Date: 2014-10-02

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 364

Registration Number: NCT02254967

Locations: 🇭🇺
Site HU36010, Budapest, Hungary
🇬🇷
Site GR30007, Athens, Greece
🇬🇷
Site GR30004, Athens, Greece

and more 106 locations

The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity

Not Applicable

Completed

Conditions: Obesity
Insulin Resistance

Interventions: Other: Placebo
Drug: Amoxicillin
Drug: Vancomycin

First Posted Date: 2014-09-16

Last Posted Date: 2020-09-10

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 57

Registration Number: NCT02241421

Locations: 🇳🇱
Maastricht University, Maastricht, Netherlands

Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

Phase 4

Conditions: Clostridium Difficile Infection

Interventions: Drug: Vancomycin
Dietary Supplement: fruit juice/placebo

First Posted Date: 2014-09-11

Last Posted Date: 2014-09-11

Lead Sponsor: Spectrum Health Hospitals

Target Recruit Count: 140

Registration Number: NCT02237859

Locations: 🇺🇸
Spectrum Health Hospital, Grand Rapids, Michigan, United States

Checklist to Prevent MRSA Surgical Site Infections

Not Applicable

Completed

Conditions: Surgical Site Infection

Interventions: Drug: Mupirocin
Drug: Chlorhexidine gluconate
Drug: Cefazolin
Drug: Vancomycin
Drug: Nasal Povidone Iodine

First Posted Date: 2014-08-13

Last Posted Date: 2021-03-11

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 1794

Registration Number: NCT02216227

Locations: 🇺🇸
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States
🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States

and more 8 locations